Mucoactive drugs and multiple applications in pulmonary disease therapy

Hocquigny, Alexis; Hugerot, Hélène; Ghanem, Rosy; Haute, Tanguy; Laurent, Véronique; Cogulet, Virginie; Montier, Tristan

doi:10.1016/j.ejpb.2023.12.001

European Journal of Pharmaceutics and Biopharmaceutics

2024

DOI: 10.1016/j.ejpb.2023.12.001

|View full text |Cite

Mucoactive drugs and multiple applications in pulmonary disease therapy

Alexis Hocquigny,

Hélène Hugerot,

Rosy Ghanem

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Rôle des agents mucoactifs dans les maladies respiratoires

Coudert

2024

Actualités Pharmaceutiques

View full text Add to dashboard Cite

Rôle des agents mucoactifs dans les maladies respiratoires

Coudert

2024

Actualités Pharmaceutiques

View full text Add to dashboard Cite

Erdosteine in the treatment of acute and chronic diseases of the respiratory system: resolution of the scientific forum of experts “In the Spotlight”

Trofimenko,

Avdeev,

Aisanov

et al. 2024

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Airway mucus hypersecretion is a pathophysiologic manifestation of acute and chronic airway inflammatory disease. Mucolytics can reduce mucus viscosity and promote mucus discharge and therefore can be considered pathogenetically based therapy.The purpose of this publication with the resolution of the scientific forum of experts was to discuss pharmacological features, efficacy, and safety of erdosteine.Results. Experts of thescientific forum not only reviewed the results of clinical trials, but also voted on the use of mucoactive drugs according to the principle of Delphi consensus. Comparison of the efficacy and safety of mucoactive drugs (erdosteine, acetylcysteine, carbocysteine, ambroxol) in patients with respiratory diseases by the experts during voting showed that the highest level of agreement among the experts was achieved for the drug Elmucin® (erdosteine) in terms of its mucolytic activity and other pharmacological features, as well as when discussing the safety of the compared drugs in the officially recommended doses. The highest level of agreement was also noted on the erdosteine efficacy in COPD patients in reducing the frequency and duration of disease exacerbations, as well as reducing the risk of hospitalization of COPD patients when used long-term as part of combination therapy. The demonstrated safety profile was the most beneficial among the reviewed mucoactive drugs.Conclusion. Elmucin® is a mucolytic with pleiotropic effects such as complex mucoactive action, potent antioxidant, anti-inflammatory and antibacterial activity with anti-adhesive effect for pathogens that determine its clinical efficacy in the treatment of acute and chronic airway diseases.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Mucoactive drugs and multiple applications in pulmonary disease therapy

Cited by 2 publications

References 71 publications

Rôle des agents mucoactifs dans les maladies respiratoires

Rôle des agents mucoactifs dans les maladies respiratoires

Erdosteine in the treatment of acute and chronic diseases of the respiratory system: resolution of the scientific forum of experts “In the Spotlight”

Contact Info

Product

Resources

About